Opinion|Videos|July 8, 2024
Adverse Event Management Practices in SCLC
Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.
Advertisement
Advertisement
Related to this article
Biomarker and preclinical data support SEZ6 as a potential therapeutic target in small cell lung cancer management.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
3
EU Approves T-DXd for HER2+ Early Breast Cancer With Residual Disease
4
Better Biomarkers Needed to Guide Neoadjuvant Chemoimmunotherapy in NSCLC
5